

September 6, 2017



# Actinium to Present at The Rodman & Renshaw 19th Annual Global Investment Conference

NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today it will present at the Rodman & Renshaw 19<sup>th</sup> Annual Global Investment Conference, sponsored by H.C. Wainwright & Co. The conference is being held September 10 – 12, 2017 at the Lotte New York Palace Hotel in New York, NY. Details regarding Actinium's presentation are as follows:

Date: Tuesday, September 12, 2017

Time: 5:30 PM ET

Room: Louis

Members of Actinium's management team will be available for one-on-one meetings with conference attendees. To arrange a meeting with management, please contact Steve O'Loughlin, Actinium's Principal Financial Officer at [soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com) or Marek Ciszewski, J.D. of Liolios Investor Relations at [marek@liolios.com](mailto:marek@liolios.com).

## About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. Actinium is

also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more about Actinium Pharmaceuticals, please visit [www.actiniumpharma.com](http://www.actiniumpharma.com) and to follow @ActiniumPharma on Twitter please visit, [www.twitter.com/actiniumpharma](http://www.twitter.com/actiniumpharma).

### **Forward-Looking Statements for Actinium Pharmaceuticals, Inc.**

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

**Contacts:**

Actinium Pharmaceuticals, Inc.  
Steve O'Loughlin  
Principal Financial Officer  
soloughlin@actiniumpharma.com

Liolios Investor Relations  
Marek Ciszewski, J.D.  
949.574.3860  
ATNM@liolios.com



Source: Actinium Pharmaceuticals